The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2020 | Prognostic value of high-sensitivity MRD assessment in CLL
Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, discusses the prognostic value of high-sensitivity MRD assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia (CLL). Based on investigations from FILO group trial findings, high-sensitivity MRD in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
